TY - JOUR
T1 - Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53
AU - Zhang, Zhongqiu
AU - Yao, Ruisheng
AU - Li, Jie
AU - Wang, Yian
AU - Boone, Charles W.
AU - Lubet, Ronald A.
AU - You, Ming
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2005/10
Y1 - 2005/10
N2 - Synergistic interaction between H-ras and p53 were systematically examined during skin tumorigenesis. Concurrent expression of an activated H-ras gene and a mutant p53 gene was accomplished by crossing p53Val135/wt mice with TG·AC mice. Topical application to wild-type mice with benzo(a)pyrene (BaP) alone produced ∼26% skin tumor incidence, whereas BaP treatment of p53wt/wtHrasTG·AC/wt, p53 Val135/wtHraswt/wt, and p53Val135/wtHras TG·AC/wt mice produced a 75%, 77%, and 100% incidence of skin tumors, respectively. An average of 0.33 tumor per mouse was observed in wild-type (p53wt/wtHraswt/wt) mice, whereas ∼1.54, 1.96, and 3.08 tumors per mouse were seen in BaP-treated p53 wt/wtHrasTG·AC/wt, p53Val135/wtHras wt/wt, and p53Val135/wtHrasTG·AC/wt mice, respectively. The effects on total tumor volume were even more striking with 7-, 48-, and 588-fold increases in tumor volume compared with wild-type (p53wt/wtHraswt/wt) in p53wt/wtHras TG·AC/wt, p53Val135/wtHraswt/wt, and p53Val135/wtHrasTG·AC/wt mice respectively. Histopathologically, all tumors from p53wt/wtHraswt/wt mice were either papillomas or well-differentiated squamous cell carcinomas, whereas the tumors in p53wt/wtHrasTG·AC/wt, p53Val135/wtHraswt/wt, and p53 Val135/wtHrasTG·AC/wt mice were principally squamous cell carcinomas with varying degree of invasiveness. Particularly, tumors in p53Val135/wtHrasTG·AC/wt mice exhibited the most rapid growth and the extreme form of tumor invasion. Microarray analysis revealed that dominant-negative p53 (Val135) and activated H-ras affected several cellular processes involved in tumorigenesis possibly through its effects on apoptosis, cell cycle arrest, and Ras-mitogen-activated protein kinase pathways. The present study provides the first in vivo evidence that a germ line p53 mutation and activated H-ras act synergistically to profoundly enhance tumor progression.
AB - Synergistic interaction between H-ras and p53 were systematically examined during skin tumorigenesis. Concurrent expression of an activated H-ras gene and a mutant p53 gene was accomplished by crossing p53Val135/wt mice with TG·AC mice. Topical application to wild-type mice with benzo(a)pyrene (BaP) alone produced ∼26% skin tumor incidence, whereas BaP treatment of p53wt/wtHrasTG·AC/wt, p53 Val135/wtHraswt/wt, and p53Val135/wtHras TG·AC/wt mice produced a 75%, 77%, and 100% incidence of skin tumors, respectively. An average of 0.33 tumor per mouse was observed in wild-type (p53wt/wtHraswt/wt) mice, whereas ∼1.54, 1.96, and 3.08 tumors per mouse were seen in BaP-treated p53 wt/wtHrasTG·AC/wt, p53Val135/wtHras wt/wt, and p53Val135/wtHrasTG·AC/wt mice, respectively. The effects on total tumor volume were even more striking with 7-, 48-, and 588-fold increases in tumor volume compared with wild-type (p53wt/wtHraswt/wt) in p53wt/wtHras TG·AC/wt, p53Val135/wtHraswt/wt, and p53Val135/wtHrasTG·AC/wt mice respectively. Histopathologically, all tumors from p53wt/wtHraswt/wt mice were either papillomas or well-differentiated squamous cell carcinomas, whereas the tumors in p53wt/wtHrasTG·AC/wt, p53Val135/wtHraswt/wt, and p53 Val135/wtHrasTG·AC/wt mice were principally squamous cell carcinomas with varying degree of invasiveness. Particularly, tumors in p53Val135/wtHrasTG·AC/wt mice exhibited the most rapid growth and the extreme form of tumor invasion. Microarray analysis revealed that dominant-negative p53 (Val135) and activated H-ras affected several cellular processes involved in tumorigenesis possibly through its effects on apoptosis, cell cycle arrest, and Ras-mitogen-activated protein kinase pathways. The present study provides the first in vivo evidence that a germ line p53 mutation and activated H-ras act synergistically to profoundly enhance tumor progression.
UR - http://www.scopus.com/inward/record.url?scp=27644506100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27644506100&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-05-0144
DO - 10.1158/1541-7786.MCR-05-0144
M3 - Article
C2 - 16254190
AN - SCOPUS:27644506100
VL - 3
SP - 563
EP - 574
JO - Molecular Cancer Research
JF - Molecular Cancer Research
SN - 1541-7786
IS - 10
ER -